Image 1
Budesonide Suspension
Product Images NDC 0093-6816
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 0093-6816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Budesonide Inhalation Suspension 0.5 mg/2 mL, 30s (6 Pouches Of Five 2 mL Vials Each) Carton, Part 1 Of 2 (Image 10)
This is a description of a medication called Budesonide Inhalation Suspension with an NDC code. The package contains six pouches of five vials each for a total of 30 unit-dose vials. The medication is used for oral inhalation only and the vials should be used within 2 weeks of opening the foil envelope. The medication should be stored at 20° to 25°C (68° to 77°F) and should not be frozen. The non-varnished area of the package contains serialization coding area, and the package should be protected from light. The medication is manufactured in England by Norton Healthcare Limited T/A IVAX Pharmaceuticals UK and is distributed by Teva Pharmaceuticals USA, Inc. The description includes instructions on how to use the medication.*
Image 2
Image 3
The text appears to be incomplete and does not provide sufficient context to generate a useful description.*
Image 4
Image 5
Image 6
Image 7
Image 8
Image 9
This is a description of Budesonide Inhalation Suspension, a medication for oral inhalation use only. It comes in 6 pouches of five 2 mL vials (30 unit-dose vials) containing 0.25 mg of micronized budesonide, USP. The medication is manufactured in England by Norton Healthcare Limited T/A IVAX Pharmaceuticals UK and is distributed in North Wales, PA by Teva Pharmaceuticals USA, Inc. The medication should be used within 2 weeks of opening the foil envelope and is intended for use only in a jet nebulizer, not an ultrasonic nebulizer. The patient should follow the Patient Instructions carefully and use it as directed by a doctor. The medication should be stored at 20° to 25°C (68° to 77°F) in a foil envelope placed upright in the carton and protected from light, and should not be frozen. Inactive Ingredients include citric acid monohydrate, disodium edetate, polysorbate 80, sodium chloride, tri-sodium citrate dihydrate, and water for injection.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
